Considerations for Developing a Zika Virus Vaccine.
From the National Institute of Allergy and Infectious Diseases, Bethesda (H.D.M., A.S.F.), and the Office of the Commissioner, Food and Drug Administration, Silver Spring (L.L.B) - both in Maryland; and the Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services, Washington, DC (N.L.).
Hilary D
HD
Marston
From the National Institute of Allergy and Infectious Diseases, Bethesda (H.D.M., A.S.F.), and the Office of the Commissioner, Food and Drug Administration, Silver Spring (L.L.B) - both in Maryland; and the Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services, Washington, DC (N.L.).
Nicole
N
Lurie
From the National Institute of Allergy and Infectious Diseases, Bethesda (H.D.M., A.S.F.), and the Office of the Commissioner, Food and Drug Administration, Silver Spring (L.L.B) - both in Maryland; and the Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services, Washington, DC (N.L.).
Luciana L
LL
Borio
From the National Institute of Allergy and Infectious Diseases, Bethesda (H.D.M., A.S.F.), and the Office of the Commissioner, Food and Drug Administration, Silver Spring (L.L.B) - both in Maryland; and the Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services, Washington, DC (N.L.).
Anthony S
AS
Fauci
D002986:Clinical Trials as Topic / Q000379:methods*; D058872:Epidemics / Q000517:prevention & control; D005260:Female; D006801:Humans; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control; D014765:Viral Vaccines / Q000276:immunology; D000071244:Zika Virus; D000071243:Zika Virus Infection / Q000453:epidemiology / Q000517:prevention & control*
D014765:Viral Vaccines